Skip to main content
Premium Trial:

Request an Annual Quote

Cambrex and XCellsyz and Sigma-Aldrich and JRH Biosciences


Cambrex Buys Immortalized Cell Line Assets from XCellsyz

Cambrex subsidiary Cambrex Bio Science Wokingham will buy conditionally immortalized cell lines and related intellectual property and equipment from British biotech XCellsyz, Cambrex said last week.

Financial terms of the deal were not disclosed.

Two weeks ago, Cambrex signed a worldwide licensing pact with Geron that will see it develop its own immortalized cell lines for distribution using Geron’s human telomerase reverse transcriptase technology (see Inside Bioassays, 1/18/2005). XCellsyz last year had signed a similar agreement for Geron’s telomerase technology, which it used to develop its own immortalized cell lines.

Cambrex said it will use the recently acquired XCellsyz technologies to immortalize a broad set of cell types, which it will sell to researchers for a variety of applications, including cell-based high-throughput drug screening and toxicity testing.

Sigma-Aldrich to Buy JRH Biosciences for $370M

Sigma-Aldrich will acquire JRH Biosciences, a division of CSL Limited, for $370 million in cash, the company said last week.

JRH, headquartered in Lenexa, Kan., supplies cell culture and sera products to the biopharmaceutical industry. It had approximately $150 million in sales in 2004, and was expecting a 10-percent growth in this figure in 2005, Sigma said.

JRH also has manufacturing facilities in the US, Europe, and Australia; and serum collection and processing centers in the US and Australia. It has approximately 400 employees worldwide.

Sigma said that it expects to fund the acquisition with a combination of existing cash, short-term debt, and three-year term debt.

Goldman Sachs acted as financial advisor on the transaction.


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.